Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days

Overview

Journal Exp Clin Endocrinol Diabetes

Specialty Endocrinology

Date 2022 Nov 7

PMID 36343645

Authors

Susanna Bianzano

Cornelia Schepers

Michael Wolff

Tim Heise

Leona Plum-Moerschel

Affiliations

Soon will be listed here.

Abstract

Objective: To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with the selective 11beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1) inhibitor BI 187004 in male and female patients with type 2 diabetes and overweight or obesity.

Methods: Randomized, double-blind, parallel-group, placebo-controlled multiple rising dose study, with 10-360 mg BI 187004 once daily over 14 days in 71 patients. Assessments included 11beta-HSD1 inhibition in the liver and subcutaneous adipose tissue ex vivo (clinical trial registry number NCT01874483).

Results: BI 187004 was well tolerated and safe in all tested dose groups. The incidence of drug-related adverse events was 51.8% (n=29) for BI 187004 and 35.7% (n=5) for placebo. There were no clinically relevant deviations in laboratory or electrocardiogram parameters besides one patient on 360 mg discontinuing treatment due to moderate supraventricular tachycardia.BI 187004 was rapidly absorbed within 2 h; exposure increased non-proportionally. The oral clearance was low, apparent volume of distribution was moderate to large, and terminal half-life with 106-124 h was rather long. Urinary tetrahydrocortisol/tetrahydrocortisone ratio decreased, indicating liver 11beta-HSD1 inhibition. Median inhibition of 11beta-HSD1 in subcutaneous adipose tissue biopsies was 87.9-99.4% immediately after the second dose and 73.8-97.5% 24 h after the last dose of BI 187004.

Conclusions: BI 187004 was safe and well tolerated over 14 days and could be dosed once daily. Targeted 11beta-HSD1 enzyme inhibition of≥80% could be shown for BI 187004 doses≥40 mg. This dose should be targeted in further studies to test blood glucose lowering in patients with type 2 diabetes and overweight or obesity.

Citing Articles

Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.

Bianzano S, Nordaby M, Plum-Morschel L, Peil B, Heise T Diabetes Obes Metab. 2022; 25(3):832-843.

PMID: 36478142 PMC: 10107759. DOI: 10.1111/dom.14932.

References

Stimson R, Andrew R, McAvoy N, Tripathi D, Hayes P, Walker B . Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes. 2011; 60(3):720-5. PMC: 3046832. DOI: 10.2337/db10-0726. View

Rask E, Olsson T, Soderberg S, Andrew R, Livingstone D, Johnson O . Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001; 86(3):1418-21. DOI: 10.1210/jcem.86.3.7453. View

Courtney R, Stewart P, Toh M, Ndongo M, Calle R, Hirshberg B . Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J Clin Endocrinol Metab. 2007; 93(2):550-6. DOI: 10.1210/jc.2007-1912. View

Gibbs J, Emery M, McCaffery I, Smith B, Gibbs M, Akrami A . Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol. 2010; 51(6):830-41. DOI: 10.1177/0091270010374470. View

Heise T, Morrow L, Hompesch M, Haring H, Kapitza C, Abt M . Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014; 16(11):1070-7. DOI: 10.1111/dom.12317. View

Shao S, Zhang X, Zhang M . Inhibition of 11β-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance. Biochem Biophys Res Commun. 2016; 478(1):474-480. DOI: 10.1016/j.bbrc.2016.06.015. View

Heise T, Graefe-Mody E, Huttner S, Ring A, Trommeshauser D, Dugi K . Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009; 11(8):786-94. DOI: 10.1111/j.1463-1326.2009.01046.x. View

Stomby A, Andrew R, Walker B, Olsson T . Tissue-specific dysregulation of cortisol regeneration by 11βHSD1 in obesity: has it promised too much?. Diabetologia. 2014; 57(6):1100-10. DOI: 10.1007/s00125-014-3228-6. View

Rosenstock J, Banarer S, Fonseca V, Inzucchi S, Sun W, Yao W . The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010; 33(7):1516-22. PMC: 2890352. DOI: 10.2337/dc09-2315. View

10.

Stewart P, Tomlinson J . Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?. Diabetes. 2008; 58(1):14-5. PMC: 2606863. DOI: 10.2337/db08-1404. View

11.

Sjostrand M, Jansson P, Palming J, de Schoolmeester J, Gill D, Rees A . Repeated measurements of 11β-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects--no change following a mixed meal. Horm Metab Res. 2010; 42(11):798-802. DOI: 10.1055/s-0030-1254134. View

12.

Paulsen S, Pedersen S, Fisker S, Richelsen B . 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007; 15(8):1954-60. DOI: 10.1038/oby.2007.233. View

13.

Hamilton B, Himmelsbach F, Nar H, Schuler-Metz A, Krosky P, Guo J . Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes. Eur J Pharmacol. 2014; 746:50-5. DOI: 10.1016/j.ejphar.2014.10.053. View

14.

Lavery G, Zielinska A, Gathercole L, Hughes B, Semjonous N, Guest P . Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2012; 153(7):3236-48. PMC: 3475725. DOI: 10.1210/en.2012-1019. View

15.

Freude S, Heise T, Woerle H, Jungnik A, Rauch T, Hamilton B . Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks. Diabetes Obes Metab. 2016; 18(5):483-90. DOI: 10.1111/dom.12635. View

16.

Anagnostis P, Athyros V, Tziomalos K, Karagiannis A, Mikhailidis D . Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009; 94(8):2692-701. DOI: 10.1210/jc.2009-0370. View

17.

Stimson R, Andersson J, Andrew R, Redhead D, Karpe F, Hayes P . Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2008; 58(1):46-53. PMC: 2606892. DOI: 10.2337/db08-0969. View

18.

Palermo M, Shackleton C, Mantero F, Stewart P . Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf). 1996; 45(5):605-11. DOI: 10.1046/j.1365-2265.1996.00853.x. View

19.

Tomlinson J, Stewart P . Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab. 2001; 15(1):61-78. DOI: 10.1053/beem.2000.0119. View

20.

Morton N . Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2009; 316(2):154-64. DOI: 10.1016/j.mce.2009.09.024. View